Quanterix Corporation (QTRX) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows mixed signals. The company has optimistic guidance and potential market expansion, but faces current financial challenges with losses and reduced cash position. The Q&A highlights concerns about government shutdown impact, market uncertainties, and lack of specific guidance. Despite these, there are positive notes on synergies, Medicare traction, and cross-selling opportunities. However, the lack of guidance and financial losses balance out the positives, leading to a neutral sentiment.
Key Financial Performance
Total Revenue for Q3 $40.2 million, an increase of 12% year-over-year. The increase was driven by the integration of Akoya and early commercial synergies.
Simoa Revenue $23 million, a 36% organic revenue decline year-over-year. The decline was due to weakness in the U.S. academic and pharmaceutical end markets.
Spatial Revenue $17.2 million, down 9% year-over-year. This includes $1.2 million of noncash revenue from an off-market contract.
Instrument Revenue $7.2 million, with $2.5 million from Simoa and $4.7 million from Spatial instruments. Sequential growth was noted, signaling a gradual recovery.
Consumable Revenue $18.8 million, consisting of $12.3 million in Simoa and $6.5 million in Spatial consumables. The decline was attributed to lower dollars per order or project despite consistent order numbers.
Accelerator Lab Revenue $8 million, with $5 million from Simoa and $3 million from Spatial. Simoa Accelerator lab revenue increased sequentially by $1 million.
Diagnostics-related Revenue $2.4 million for the quarter, reflecting progress in Alzheimer's diagnostics and partnerships in Asia.
Gross Profit and Margin $17.2 million and 42.8%, respectively. Non-GAAP gross profit was $18.5 million and non-GAAP gross margin was 45.9%. The alignment of Akoya's accounting policies caused a reduction in gross margins, offset by synergies.
Operating Expenses $54.5 million, including $15 million of costs related to acquisition, integration, restructuring, and purchase accounting. Non-GAAP operating expenses were $38.2 million, an increase of $7.1 million sequentially.
Adjusted EBITDA A loss of $11.9 million compared to a loss of $5.5 million in the third quarter of the prior year. The loss reflects increased spending and integration costs.
Cash Position $138 million at the end of the quarter. Adjusted cash usage during the quarter was $16.1 million, with $126 million spent on deal-related costs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Alzheimer's diagnostics: Significant investments made, including advancing Alzheimer's diagnostics programs and receiving a positive pricing recommendation for the LucentAD test at $897. Added 4 diagnostics partners in Asia to expand reach.
New assays: Investments in new assays across Simoa and Spatial franchises. Early access program for Simoa One to be launched soon.
Market stabilization: Signs of stabilization in academic, government, and pharma markets. Early activity in oncology with applications in liquid biopsy and tumor profiling.
Geographic expansion: Added 4 diagnostics partners in Asia to extend reach and make biomarker testing available to more patients worldwide.
Integration of Akoya: Achieved $67 million of the $85 million in targeted cost synergies. Consolidated four manufacturing and lab service operations into two sites. Unified leadership and infrastructure.
Revenue performance: Generated $40 million in Q3 revenue, with instrumentation and accelerator revenues showing sequential growth.
Strategic alignment: Integration of Simoa and Spatial portfolios under one umbrella, creating cross-selling opportunities and expanding presence in pharma and academic markets.
Cost management: Disciplined cash management with a target to finish the year with $120 million in cash and no debt. Expected to be cash flow breakeven in 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Integration Challenges: The company is undergoing significant integration work following the acquisition of Akoya. While progress has been made, such large-scale integrations inherently carry risks such as operational disruptions, cultural misalignment, and delays in achieving synergies.
Market Demand Uncertainty: Demand across the broader industry remains uneven, particularly in U.S. academic and pharmaceutical end markets, which have seen significant revenue declines. This uneven demand could impact future revenue stability.
Revenue Decline in Key Segments: Simoa experienced a 36% organic revenue decline, and Spatial reported a 9% year-over-year decline. Weakness in U.S. academic and pharmaceutical markets contributed to these declines, driven by reduced academic grants and lower pharma spending.
Profitability Pressures: The company reported a non-GAAP operating expense increase of $7.1 million sequentially, and adjusted EBITDA showed a loss of $11.9 million compared to a $5.5 million loss in the prior year. These factors indicate ongoing profitability challenges.
R&D Investment Risks: The company is making significant R&D investments, including $27 million year-to-date, which is nearly 30% of revenue. While these investments aim to drive future growth, they also pose risks if the expected returns are not realized.
Regulatory and Pricing Risks: The company awaits final approval for the pricing of its LucentAD test at $897. Delays or unfavorable decisions could impact the financial performance of its Alzheimer's diagnostics program.
Supply Chain Consolidation Risks: The integration of supply chains into one manufacturing operation and one lab carries risks of operational inefficiencies or disruptions, which could impact product delivery and customer satisfaction.
Cash Flow and Liquidity Risks: Although the company expects to end the year with $120 million in cash and no debt, adjusted cash usage during Q3 was $16.1 million. Continued cash burn could pose liquidity challenges if not managed effectively.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company expects to report $130 million to $135 million of revenue for 2025, with approximately $100 million to $105 million from Simoa. Pro forma revenue is projected to be $165 million to $170 million for 2025, assuming the two companies were combined for the full year.
Gross Margin Projections: GAAP gross margin is expected to range between 45% and 47%, with non-GAAP gross margin in the same range for 2025.
Cash Position and Usage: The company expects adjusted cash usage of $34 million to $38 million for the full year 2025. It plans to end 2025 with approximately $120 million in cash and no debt.
Alzheimer's Diagnostics: The company is advancing its Alzheimer's diagnostics programs, including the LucentAD test, which received a positive pricing recommendation at $897. A final approval decision is expected later this quarter.
Product Launches: An early access program for the Simoa One platform will be launched soon, allowing key partners to experience the technology and provide feedback ahead of a broader launch.
Market Trends and Recovery: Signs of stabilization are observed in academic, government, and pharma markets, with gradual recovery expected over the next few quarters. Early activity in oncology and multimodal biomarker strategies is also noted.
Integration and Synergies: The company has realized $67 million of the $85 million in targeted cost synergies from the Akoya acquisition and expects further benefits from integration activities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why were Simoa consumables down 30% year-over-year?
A:The order volume was consistent with last year, but the order size was smaller due to smaller project sizes in the academic grant environment. This trend was also observed in the Accelerator side, with smaller project scopes expected to scale in 2026.
Q:What are the plans for implementing synergies in Q4 2025?
A:The company has already implemented a single manufacturing team and combined lab services under one footprint. Additional synergies are expected as the company integrates into a single ERP system by early next year, aiming for $85 million in total synergies.
Q:What is the outlook for the diagnostics business and Medicare coverage?
A:The company expects to gain traction with durable Medicare coverage and a payment rate close to $897. They are focusing on clinical utility studies to demonstrate the value of their five-marker algorithmic test, with more traction expected in 2026.
Q:What are the assumptions for Akoya business in Q4?
A:The company modeled a slight step down in Q4 revenue due to market uncertainty and funding delays, despite solid execution in Q3 with $17 million in revenue.
Q:Was there any pull-forward in Akoya's Q3 performance?
A:No, the $17 million in Q3 revenue was attributed to solid execution without any material pull-forwards.
Q:What is the outlook for core Quanterix in Q4?
A:The company maintained its full-year guidance, being prudent due to government shutdown risks and market uncertainties. Sequential improvement was observed in Q3, particularly in Accelerator and Instruments, with optimism for 2026.
Q:What is the status of cross-selling opportunities?
A:Early cross-selling opportunities have been positive, with Simoa customers showing interest in Spatial products and vice versa. The company is tracking a double-digit list of opportunities.
Q:When will 2026 guidance be provided?
A:The company plans to provide 2026 guidance during the last quarter call for the year.
Q:How is the government shutdown impacting Q4 guidance?
A:The government shutdown was factored into Q4 guidance, leading to a slight deceleration. If the shutdown ends sooner, it could provide slight upside.
Q:How does the company plan to address competition in the high-sensitivity, high-multiplex platform market?
A:The company focuses on the 4-5 marker translational segment rather than the high-plex discovery market. They see high-plex discovery as beneficial for identifying new markers that feed into their pipeline.
Q:What is the update on LucentAD volume and pricing?
A:The company has not disclosed direct testing revenues and volumes but expects established pricing to drive stronger traction in 2026. Enablement partners are showing steady business growth.
Q:What is the difference between cost reductions implemented and realized?
A:Cost reductions implemented refer to the full-year impact of actions, while realized reductions are the actual savings within the quarter.
Q:What is the outlook for instrument placements and lab services?
A:Lab services are expected to rebound ahead of instrument placements, with an increase in Accelerator projects already observed. Instruments performed well, and the company aims to place them globally.
Q:What is the timeline for Simoa One and its revenue contribution?
A:An early access program for Simoa One will start before the end of the year, with revenue contribution updates expected in the next quarter call.
Q:What is the update on LucentAD in Asia?
A:The company is in early stages but seeing opportunities in China, where partners have received IVD approval and are testing patients.
Q:Will R&D spending increase in 2026?
A:The company plans to maintain strategic investments in growth areas like Simoa One, diagnostics, and assay development, balancing R&D as a priority item.
Q:Review of Unclear Management Responses
A:Management avoided providing specific 2026 guidance during the call, stating it would be shared in the last quarter call for the year. Additionally, they did not disclose direct testing revenues and volumes for LucentAD, indicating they would do so when it becomes material, likely next year.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Akoya accounting
Akoya allocation
Akoya cost
Akoya excludes
Akoya month
Akoya rate
Akoya week
Alzheimer diagnostics
Asia reach
Diagnostics step
Instrument Simoa
Instrumentation accelerator
LucentAD test
Non increase
RD
Simoa Spatial
Simoa instrument
acquisition Akoya
activity
alignment
allocation change
biomarker
cash debt
cost synergy
forma
foundation
improvement cash
instrument Simoa
integration milestone
loss
manufacturing
momentum
order
profitability
program
realization
reduction
start
tissue blood
track cash
transaction
QTRX Transcript
Quanterix Corporation (QTRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
Quanterix Corporation (QTRX) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call reveals positive financial metrics with a 15% revenue increase and improved gross margins, yet a net loss persists. The lack of guidance and forward-looking statements indicating risks introduce uncertainty. The absence of strategic updates or shareholder return plans limits positive sentiment. Overall, the company's performance shows improvement, but the lack of clear guidance and persistent net loss result in a neutral sentiment. Without market cap data, the reaction is uncertain, but the improvements are not strong enough to predict a significant positive stock movement.
Quanterix Corporation (QTRX) Q4 2025 Earnings Call Transcript
Positive3-3
The earnings call indicates a strong financial performance with a 12% revenue increase, improved gross margins, and reduced net loss. Positive cash flow from operations and strategic investments in R&D support growth prospects. Despite acknowledging risks in forward-looking statements, the overall sentiment is positive due to improved financial metrics and operational efficiency.
Quanterix Corporation (QTRX) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call summary shows mixed signals. The company has optimistic guidance and potential market expansion, but faces current financial challenges with losses and reduced cash position. The Q&A highlights concerns about government shutdown impact, market uncertainties, and lack of specific guidance. Despite these, there are positive notes on synergies, Medicare traction, and cross-selling opportunities. However, the lack of guidance and financial losses balance out the positives, leading to a neutral sentiment.
QTRX Slides
QTRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
